$66.23
3.06% today
Nasdaq, Apr 04, 09:47 pm CET
ISIN
US6707031075
Symbol
NUVL
Sector
Industry

Nuvalent Inc - Ordinary Shares - Class A Stock price

$68.32
-2.71 3.82% 1M
-35.18 33.99% 6M
-9.96 12.72% YTD
-5.68 7.68% 1Y
+53.25 353.35% 3Y
+49.57 264.37% 5Y
+49.57 264.37% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-2.14 3.04%
ISIN
US6707031075
Symbol
NUVL
Sector
Industry

Key metrics

Market capitalization $4.89b
Enterprise Value $3.77b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.56
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-280.37m
Free Cash Flow (TTM) Free Cash Flow $-185.06m
Cash position $1.12b
EPS (TTM) EPS $-3.91
P/E forward negative
Short interest 20.11%
Show more

Is Nuvalent Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Nuvalent Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Nuvalent Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 63 63
73% 73%
-
- Research and Development Expense 218 218
92% 92%
-
-280 -280
88% 88%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -280 -280
88% 88%
-
Net Profit -261 -261
107% 107%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nuvalent Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nuvalent Inc - Ordinary Shares - Class A Stock News

Neutral
PRNewsWire
3 days ago
CAMBRIDGE, Mass. , April 1, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
Neutral
PRNewsWire
10 days ago
CAMBRIDGE, Mass. , March 25, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced upcoming poster presentations further characterizing the preclinical profiles of its novel ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibit...
Neutral
PRNewsWire
about one month ago
CAMBRIDGE, Mass. , Feb. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
More Nuvalent Inc - Ordinary Shares - Class A News

Company Profile

Nuvalent, Inc. operates as a preclinical stage biopharmaceutical company. The company creates precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Its focus its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. The company was founded in January 2017 and is headquartered Cambridge, MA.

Head office United States
CEO James Porter
Employees 142
Founded 2017
Website www.nuvalent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today